Cargando…
Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis
BACKGROUND: With the emergence of disease-modifying Alzheimer’s treatments, timely detection of early-stage disease is more important than ever, as the treatment will not be indicated for later stages. Contemporary population-level data for detection rates of mild cognitive impairment (MCI), the sta...
Autores principales: | Mattke, Soeren, Jun, Hankyung, Chen, Emily, Liu, Ying, Becker, Andrew, Wallick, Christopher |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362635/ https://www.ncbi.nlm.nih.gov/pubmed/37481563 http://dx.doi.org/10.1186/s13195-023-01272-z |
Ejemplares similares
-
Projection of budgetary savings to US state Medicaid programs from reduced nursing home use due to an Alzheimer's disease treatment
por: Lam, Jenny, et al.
Publicado: (2021) -
Medicare's Annual Wellness Visit and diagnoses of dementias and cognitive impairment
por: Thunell, Johanna A., et al.
Publicado: (2022) -
Is Korea Prepared for an Alzheimer’s Disease-Modifying Therapy? Assessing the Korean Healthcare System Infrastructure and the Effect of Blood-Based Biomarker Tests
por: Jun, Hankyung, et al.
Publicado: (2021) -
Life expectancy and active life expectancy by marital status among older U.S. adults: Results from the U.S. Medicare Health Outcome Survey (HOS)
por: Jia, Haomiao, et al.
Publicado: (2020) -
Projecting the long‐term societal value of a disease‐modifying treatment for Alzheimer's disease in the United States
por: Prados, Maria J., et al.
Publicado: (2022)